AKTX Akari Therapeutics

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Akari Therapeutics

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Akari Therapeutics (NASDAQ: AKTX) concerning possible violations of federal securities laws.

On April 26, 2017, Edison Research Ltd. issued a report on Akari called “Akari’s Coversin matches Soliris in Phase II.” The following day, it was announced the report had been withdraw due to “material inaccuracies.” Then on May 11, 2017, the Company announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb had any involvement with the materially inaccurate research report. To obtain additional information, go to:

http://zlk.9nl.com/akari-therapeutics-aktx

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
12/05/2017

Underlying

AKTXAkari Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Akari Therapeutics

 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI THERAPEUTICS 96 HOUR DEADLINE ALERT: Approximately 96 Hours Rema...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with large financial interests that they have only until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX). Investor losses must relate to purchases of the Company’s securities between March 30, 2017 and May 11, 2017. This action is pending in the United States District Court for the Southern ...

July 8, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

July 5, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages I...

NEW YORK--(BUSINESS WIRE)-- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX) of the July 11, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you invested in Akari American Depository Receipts (“ADRs”) between March 30, 2017 and May 11, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no co...

June 19, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

AKARI THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney Gene...

NEW ORLEANS--(BUSINESS WIRE)-- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 11, 2017 to file lead plaintiff applications in a securities class action lawsuit against Akari Therapeutics, Plc (NasdaqCM: AKTX), if they purchased the Company’s securities between March 30, 2017, and May 11, 2017, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York. ...

June 17, 2017 1 EN
 PRESS RELEASE
Free
AKTX Akari Therapeut...

Akari Therapeutics Announces Resignation of CEO

NEW YORK & LONDON--(BUSINESS WIRE)-- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, today announced the resignation of Gur Roshwalb, the Company’s Chief Executive Officer, and correction to fifth patient data in the Company’s press release issued on April 24, 2017 (the “Release”). As previously reported by the Company, its Board of Directors established an ad hoc special committee of the Board to review the involvement, if any, of Company personnel with the report issued by ...

May 30, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch